Nexalin Technology, Inc. (NXL) company profile
Close on Nov 18, 2026Market cap $31.73MP/E –Yield –
About Nexalin Technology
Electromedical & Electrotherapeutic Apparatus, SIC 3845
Nexalin designs and creates bioelectronic neurostimulation medical devices designed to address mental health conditions including anxiety, depression, and insomnia without pharmaceutical drugs or psychotherapy. Its core technology utilizes non-invasive electrical waveforms emitted through patient headsets and clinical systems. Offerings include its original Generation 1 cranial electrotherapy stimulation unit, alongside its advanced Generation 2 SYNC clinical console and Generation 3 HALO at-home headset systems. The company also supplies single-use radio-frequency identification electrodes, patient cables, and related licensing services. Customers comprise healthcare providers and licensed medical professionals who administer treatments in clinics or prescribe devices for home use via virtual clinic platforms.
Management and operating facilities are located at the company's headquarters in Houston, Texas. Beyond its domestic presence, the company maintains international regulatory approvals and operations across several jurisdictions. Its Generation 2 medical device holds regulatory clearance in Oman and Brazil, and approval in China through the National Medical Products Administration. Furthermore, clinical trials, marketing, and distribution throughout China and neighboring territories are conducted through a Hong Kong-registered joint venture, supported by a wholly foreign-owned enterprise office in the People's Republic of China.
Summary of the business section of Nexalin Technology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nexalin Technology, Inc.
- Founded
- 2010
- Headquarters
- Houston, TX
- Address
- 1776 Yorktown, Suite 550 77056
- Phone
- (832) 260-0222
- Website
- nexalin.com
- Employees
- 8, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum llp, Marlton, New Jersey
Stock & identifiers
- Ticker
- NXL
- Exchange
- Nasdaq
- IPO date
- Sep 19, 2022
- Shares outstanding
- 22M, Aug 10, 2026
- Public float
- $14.73M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-30 reverse, Aug 31, 2026
- SEC CIK
- 1527352
- CUSIP
- 65345B300
- ISIN
- US65345B3006
- FIGI
- BBG014CRDGH9
- Share class FIGI
- BBG014CRDHD1
- EIN
- 27-5566468
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mark White | CEO, Director | 309,127 |
| David Owens | Chief Medical Officer, Director | 191,252 |
| Carolyn Hamby Shelton | Sr. VP - Quality - Regulatory | 54,000 |
| Fleet Justin Van | CFO | 25,000 |
| Alan Kazden | Director | 119,590 |
| Ben Hu | Director | 381,261 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Mark White Chief Executive Officer | $300.00K | $280.00K | $241.48K | $18.00K | $839.48K | -18% |
| David Owens, M.D. Chief Medical Officer | – | – | $450.08K | $50.60K | $500.68K | -43% |
| Carolyn Shelton Senior Vice-President of Quality, Clinical and Regulatory | $300.00K | $40.00K | $51.18K | – | $391.18K | +36% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 19, 2022
- Offer price
- $4.15
- Securities offered
- 2,315,000
- Gross proceeds
- $9.61M
- Exchange
- Nasdaq
- First trading day
- Sep 16, 2022
- First-day close
- $2.25-45.8%
- Lock-up ends (est.)
- Mar 15, 2023
“We are offering 2,315,000 units at an offering price of $4.15 per unit.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 8 full-time employees, our CMO is a consultant and we utilize varying levels of other consultants.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?